Hi everyone I'm sharing our most recent 16 minutes episode here because it covers

vaccines a topic that we've covered here since January of last year in our early

and ongoing pandemic coverage as part of our mission to continue bringing you everything

you need to know about this crisis and how tech, and in this case bio, changes our future.

You can find our past coverage at a six and C.com slash coronavirus and a six and

and com slash vaccines, but in the discussion that follows the team digs into vaccine

efficacy and frameworks given the third emergency use authorization approved vaccine. and 16 minutes. I'm Zoran and our topic today is the ongoing buzz and the mixed

news around the Johnson and Johnson vaccine, which was the third vaccine for

COVID approved under emergency use authorization by the FDA just a few weeks ago, and which Johnson and Johnson reported in its press release as the first single shot vaccine, and as having 85% efficacy in preventing severe disease across region studied.

Meanwhile, Stat headlines reported 66% efficacy overall

and 72% in the US in preventing moderate to severe disease,

with their headline saying it is, quote, a weapon but not a knockout punch.

And then we have various experts saying everything from quote, disappointing to pointing out the

dangers of comparing this vaccine to other vaccines, such as Pfizer's and Modernas,

both of which we've talked about on this show.

You can find all our ongoing vaccines coverage

at A16Z.com slash vaccines.

But in this episode, since 16 minutes is about teasing apart what's hyp and what's real in the news and where we are in the

long arc of innovation, we ask the A16Z bio team for their frameworks.

General partner Jorge Conde joins us.

He's been in all of our vaccine episodes

and he also previously led strategy and product

...